STAT+: French regulator fines Novo and Lilly over weight loss ad campaigns

France's medicines regulator fined Novo Nordisk approximately $2 million and Eli Lilly roughly $127,000 for misleading advertisements for their weight loss medications. The penalties reflect increasing concern among regulators that weight loss medicines may be misused. The regulator is closely scrutinizing promotions run by pharmaceutical companies.